David Simpson, MBChB, FRACP, FRCPA, is Senior Medical Director at BeiGene, a biotechnology company based in San Francisco, CA. Dr Simpson worked as a Hematologist at the Harbour Cancer Centre (2018-2019) and the North Shore Hospital (2000-2019) in Auckland, New Zealand.
Dr Simpson has a Bachelor of Medicine and Bachelor of Surgery (MBChB) from the University of Auckland (1981-1986). He was a Fellow of The Royal College of Pathologists Australasia (FRCPA) (1991-1996) and from the Royal Australasian College of Physicians (FRACP). From 1997 to 2000, he was an Assistant Professor at the Rush University Medical Center in Chicago, IL. He is also a member of The Castleman Disease Collaborative Network (CDCN) Scientific Advisory Committee.
Speaking on myeloma and lymphoma
Dr Simpson is interested in malignant hematology and is internationally recognized in the field of multiple myeloma and chronic lymphocytic leukemia (CLL). His research focuses on clinical evaluations of new treatments. Dr Simpson is the principal investigator in three clinical trials evaluating Bcl-2 inhibitors in mature B-cell malignancies and bendamustine and rituximab (BR) in chronic lymphocytic leukemia (NCT04277637, NCT04771130, NCT03847727).